Galanthamine treatment in Alzheimer’s disease
18 patients who had fullfilled the NINCDS-ADRDA criteria for “possible AD” took part in a clinical study to evaluate the effect of the cholinesteraseinhibitor Galanthamine, 30 mg/day. Neuropsychological and social parameters were rated. This open clinical pilot-study showed no statistic significant change in neuropsychological test-results. However after 1 year treatment 6 patients are still taking the drug. According to their care-persons there was a positive changes in competence of everyday-routine and/or in the emotional situation.
KeywordsCholinergic Neuron Senile Dementia Memory Score Emotional Situation Choline Acetyl
Unable to display preview. Download preview PDF.
- Dal-Bianco P, Maly J, Deecke L (1988) THA-Therapie bei Patienten mit seniler Demenz vom Alzheimer-Typ. Wien Klin Wochenschr 100 (12): 415Google Scholar
- Davies P, Maloney AJF (1976) Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet ii: 1403Google Scholar
- Summers WK, Majovski LV, Marsh GM, et al (1986) Oral THA in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 315: 1241–1245Google Scholar
- Thomsen T, Bickel U, Fischer JP, Kewitz H (1991) Tolerance and inhibition of cholinesterases by Galanthamine in healthy volunteers and Alzheimer patients (in apress)Google Scholar